SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...
The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
Bernstein lowered the firm’s price target on Pfizer (PFE) to $30 from $32 and keeps a Market Perform rating on the shares. The firm notes ...
GlobalData on MSN1d
Pfizer sets sights on Summit’s bispecific in combo with its ADCsPfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s ivonescimab in combination with several ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
We recently compiled a list of the Jim Cramer Remembers COVID-19 & Discusses These 11 Stocks. In this article, we are going ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback